Related Experiment Videos
[Surgical analysis for lung cancer with scalene node metastasis]
T Okubo1, T Okayasu, N Hasegawa
1Second Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan.
Kyobu Geka. the Japanese Journal of Thoracic Surgery
|November 1, 1993
Summary
This study on lung cancer with scalene node metastasis found a 14.3% five-year survival rate after lobectomy. Survival outcomes highlight the challenges of advanced lung cancer treatment.
Area of Science:
- Oncology
- Thoracic Surgery
- Pathology
Context:
- Scalene lymph node metastasis indicates advanced lung cancer.
- Surgical intervention, specifically lobectomy, was analyzed in these cases.
- The study included 15 patients with varying tumor locations and types.
Purpose:
- To evaluate the outcomes of surgically treated lung cancer patients with scalene node metastasis.
- To determine the survival rates and periods in this patient cohort.
- To analyze the impact of lobectomy on survival in advanced lung cancer.
Summary:
- Fifteen lung cancer patients with scalene node metastasis underwent lobectomy.
- Histological types included adenocarcinoma, squamous cell, and large cell carcinoma.
- The five-year survival rate was 14.3%, with an average survival of 26.6 months.
Impact:
- Findings underscore the poor prognosis for lung cancer with lymph node metastasis.
- Highlights the limited long-term survival benefit of lobectomy in such advanced cases.
- Provides data for understanding survival patterns in surgically treated advanced lung cancer.